Terry C. Vance
Independent DirectorMr. Terry C. Vance serves as a Director of Ardais Corporation, Rib-X and CytoLogix Corporation. Mr. Vance is also a Board observer of Rib-X. He serves as a Member of Advisory Board of Mountain Group Capital LLC and Limestone Fund, LLC. Mr. Vance served as Chief Business Officer at BioMotiv, LLC since June 2013 till November 2018. As a Venture Partner of Saints Capital, Mr. Vance led the structuring and secondary purchase of a portfolio of life science companies from a leading venture capital firm and has co-managed the portfolio since its acquisition in 2011. Until January 2018, he served as a Managing Member at EGS Healthcare Capital Partners, L.L.C. He Co-founded EGS in 2000. Before starting EGS Healthcare, Mr. Vance was a founding Partner in Eagle Advisors, which provided strategic advice to emerging biotech companies that included Amylin and Corixa. He worked at StoneyHill Ventures, where he provided strategic and investment advice to a number of healthcare companies and Investors, including Goldman Sachs’ Merchant Bank and Quintiles Transnational, Inc. Mr. Vance was an investment banker, first at Salomon Brothers and then at Goldman Sachs, where he was a vice president in the Capital Markets Division. Mr. Vance also managed private equity distribution at Goldman Sachs and was later a Group Head within the Capital Markets Division responsible for the Northeastern United States, where he was a Strategic Advisor to several pharmaceutical companies including Merck, Warner-Lambert, American Cyanamid, SmithKline Beecham and Rhone-Poulenc Rorer. He has been an Independent Director at Enanta Pharmaceuticals, Inc. since June 2011. He served as a Director at CircuLite, Inc., Endius, Inc. and Healthcare IT, Inc. He is a contributing editor to Diabetes Close-Up, an industry publication focused on metabolic disease, especially diabetes and obesity. Mr. Vance holds an M.B.A. from Stanford University and an A.B. Degree with high honors, from Princeton University.
Positions
- Company NameEnanta Pharmaceuticals, Inc.Stock CodeENTAPositionIndependent DirectorColleagues
- JRJay R. LulyPresident, CEO & Director
- BLBruce Leonard Andrews CarterIndependent Non-Executive Chairman
- YSYat Sun OrChief Scientific Officer
- STScott T. RottinghausChief Medical Officer
- HRHarry R. TroutVP of Finance & Interim Principal Financial Officer
- TLTara Lynn KiefferChief Operating Officer
- KPKristine PetersonIndependent Director
- MGMark G. FolettaIndependent Director
